Valneva posts positive early clinical data for adjuvanted COVID-19 vaccine

By The Science Advisory Board staff writers

April 6, 2021 -- Valneva is directing attention to positive results from the phase I/II clinical trial of its VLA2001, an inactivated, adjuvanted COVID-19 vaccine candidate.

The clinical trial -- VLA2001-201 -- included 153 healthy adults ages 18 to 55 years and evaluated three different dose levels of VLA2001 based on a schedule of two doses injected three weeks apart. VLA2001 was deemed to be generally safe and well-tolerated.

What's more, it was found to be highly immunogenic; more than 90% of all study participants developed significant levels of antibodies to the SARS-CoV-2 virus spike protein across all dose groups tested, according to the company. Based on the study results, Valneva said it plans to initiate a pivotal, comparative immunogenicity phase III trial by the end of April for the high-dose level of VLA2001, subject to regulatory approval.

Valneva noted that it now believes that the timeline for delivery of 60 million doses of vaccine to the U.K. government will extend into the first quarter of 2022. Antigen sparing options are also being investigated for booster strategies based on the phase I/II data.

The aim now is to complete a regulatory licensure submission for VLA2001 to the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K. in the autumn, according to the firm. Discussions with other regulatory bodies are ongoing, Valneva said.

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...
Dynavax helps advance COVID-19 vaccine candidates
Dynavax Technologies said it will be providing additional quantities of its CpG 1018 adjuvant for Valneva's SARS-CoV-2 vaccine candidate and has also...
Valneva begins COVID-19 vaccine production
Valneva has begun production of its inactivated COVID-19 vaccine candidate in conjunction with ongoing clinical studies from which the company expects...
Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.

Copyright © 2021

SLAS2022 International Conference & Exhibition
February 5-9
Boston, Massachusetts United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter